In a postmortem study of 55 patients with MS (mean age 57.5 years), DeLuca et al. investigated the nature of axonal loss in relation to plaque formation. They carried out histological staining for ...

Chronic, irreversible motor disability in patients with multiple sclerosis (MS) correlates with axonal pathology rather than demyelination, according to new research. During the early stages of MS ...

When patients are diagnosed with MS and have their first neurological symptoms, axonal loss has already occurred. 6 Because brain atrophy, specifically gray matter atrophy, creates permanent ...

Compared to patients with adult-onset MS, those with pediatric onset had a more rapid decline in information-processing efficiency and a higher likelihood of cognitive impairment.

Lead researcher Klaus Schmierer said: "The lack of association between axonal loss and spinal cord cross sectional area significantly changes our understanding of chronic disability in MS.

Imaging studies at the NIH Clinical Center showed that chronic active lesions with a paramagnetic rim exerted ongoing tissue ...

Results from the Balcer study also suggest that the 'unaffected' eyes of patients with MS who have a history of AON are at a similar risk for axonal loss to the eyes of patients with MS in general ...

Early treatment retards or even arrests the "ABCDs" that can take place in MS: axonal loss, brain atrophy, cognitive dysfunction, and disability. [1] ...

Multiple sclerosis affects more than 2 million people worldwide and is currently incurable. A number of interventions to modify the course of multiple sclerosis have been developed that offer new i ...

Multiple sclerosis is a common and, in many cases seriously disabling, autoimmune disease that can lead to the disturbance or loss of sensory function, voluntary movement, vision and bladder control.

For patients with acute optic neuritis, measuring early optic nerve lesion length may predict neuro-axonal loss and serve as a biomarker for chronic visual impairment in the future.

"Therapeutics must target remyelination and prevent further axonal degeneration and neuronal loss. The good estrogens, which have neuroprotective and immunomodulatory benefits, could be candidates ...